Group 1 - The Hong Kong pharmaceutical stocks experienced a collective decline, with notable drops in specific companies [1] - Three-Sixty Pharmaceuticals (01530.HK) fell over 8%, indicating significant market pressure [1] - China Biopharmaceutical (01177.HK) decreased by more than 2%, reflecting a broader trend in the sector [1] Group 2 - Hansoh Pharmaceutical (03692.HK) and CSPC Pharmaceutical Group (01093.HK) both saw declines exceeding 1%, contributing to the overall downturn in the industry [1]

导 · 读 本周 江苏、四川、北京、浙江 等 地均有母基金 宣布设立或完成备案， 母基金主要聚焦在 人工智能、 低空经济、新能源、电子信息、数字经济、生物医药、先进制造等领域。 基金设立层面，本周 上海、北京、合肥、南宁、武汉、天津等地区均有基金宣布设立或完成注册， 基金主要投资赛道包括： 人工智能、集成电路、高端制造、新一代信息技术、新能源、新材料、集 成电路、地空经济。 值得关注的是，本周两家高校宣布设立基金。其中 上海交大发起设立「交大-云启AI天使基金」，武 汉理工大学发起10亿元科创基金。 105亿，苏州战新基金二期要来了 近日，江苏省、苏州市正式审议通过第二批苏州市战略性新兴产业基金组建方案，第二批4只总规 模105亿元苏州市战新基金正式进入落地阶段。 1.苏州人工智能产业专项母基金 拟落地工业园区。工业园区作为国家人工智能创新发展试验区核心区，已构建"芯片研发-算法开 发-场景应用"全链条产业生态，集聚1800多家企业，2024年产值突破1200亿元，行业内形成显著 领先优势。 2.苏州低空经济产业专项母基金 拟落地张家港。张家港新能源产业集群效应突出，形成了"光伏产业、锂电产业、氢能产业、新能 ...

根据公开信息统计：截至周五下午，本周（4月19日-4月25日）LP动态共28起。 LP 上海国资，一举投6家GP 近 日 ， 上 海 未 来 产 业 基 金 发 布 公 告 ， 基 金 拟 参 与 投 资 6 只 子 基 金 ， 覆 盖 脑 科 学 、 合 成 生 物 学、硬科技等前沿领域。这6只子基金分别为：上海博联脑科学产业创业投资合伙企业（有 限合伙）、上海安福创生合成生物学创业投资合伙企业（有限合伙）、木华水清（上海）创 业投资合伙企业（有限合伙）、上海峰瑞睿佳投资中心（有限合伙）、上海联想未来创业投 资基金合伙企业（有限合伙）及中科创星硬科技（上海）股权投资合伙企业（有限合伙）。 上海未来产业基金的1 0 0亿元由上海市财政全额出资，定位于搭建推动颠覆式创新、多学科 交叉创新、前沿平台性技术方向孵化和早期投资的开放赋能平台，关注科学属性强、转化风 险大、现有产业化条件缺乏，但迭代迅速、有机会产生巨大变革的技术。 LP 苏州1 0 0亿母基金来了 「解码 LP 」系投资界旗下专注 LP 报道公众号，关注各地基金政策，捕捉 LP 最新动态，欢迎关注！ 近日，台州嘉道智能壹号私募股权投资基金合伙企业（有限 ...

以下文章来源于LP波谱 ，作者王满华 LP波谱 . 本账号专注LP市场报道。"波浪、谱系"是识别市场的维度，也是定义市场的坐标；此外，波谱（Pop Art）也意为放低意义与史诗的执念，认同商业的日常 之美。 将投中网设为"星标⭐"，第一时间收获最新推送 聚焦LP出资、新基金、GP招募，捕捉LP圈一周商业情报。 作者丨 王满华 来源丨LP波谱 今年2月，江苏省战略性新兴产业母基金第二批产业专项基金集中举办了签约仪式，总规模高达408亿元。 在当时的官方报道中，省级母基金共在11个设区市和4户省属企业设立了22只专项基金。其中，苏州国资代表——苏创投集团与江苏高投集团签约了4只 专项基金，总规模105亿。 时隔两个月，这4只基金于本周正式进入落地阶段。 具体来看，4只基金分别为：总规模60亿元的苏州人工智能产业专项母基金，总规模20亿元的苏州低空经济产业专项母基金，总规模20亿元的苏州新型能 源及智能座驾产业专项母基金，以及总规模5亿元的苏州高校科技成果转化天使基金。 上述专项母基金的设立，无疑将为苏州产业发展、GDP增长再添一把火。 另外，总规模30亿元的江苏省节能环保战新产业基金也在本周完成备案，该基金同样属 ...

Core Viewpoint - China Biopharmaceutical has received FDA approval for its drug, Paimapril monoclonal antibody injection, for specific cancer treatments [1] Group 1: FDA Approval Details - The Paimapril monoclonal antibody injection is approved for use in combination with cisplatin or carboplatin and gemcitabine for first-line treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) in adult patients [1] - It is also approved as a monotherapy for adult patients with metastatic non-keratinizing nasopharyngeal carcinoma who have experienced disease progression during or after platinum-based chemotherapy and have received at least one prior treatment [1]

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant increases in constituent stocks and a notable rise in the Hang Seng Healthcare ETF, reflecting positive market sentiment and growth potential in the healthcare sector [3][4]. Group 1: Market Performance - As of April 25, 2025, the HSHCI rose by 1.77%, with notable gains from stocks such as Yidu Tech (10.15%) and WeDoctor (7.05%) [3]. - The Hang Seng Healthcare ETF (513060) opened high and increased by 2.68%, marking its fifth consecutive rise, with a latest price of 0.50 yuan [3]. - Over the past week, the Hang Seng Healthcare ETF has accumulated an 8.50% increase [3]. Group 2: Liquidity and Trading Volume - The Hang Seng Healthcare ETF had a turnover rate of 1.57% during the trading session, with a transaction volume of 183 million yuan [3]. - The ETF's average daily trading volume over the past month was 2.072 billion yuan, ranking first among comparable funds [3]. Group 3: Policy and Industry Outlook - On April 24, 2025, the Ministry of Industry and Information Technology and six other departments issued a notice on the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)," aimed at enhancing the integration of AI and new information technologies within the pharmaceutical industry [3]. Group 4: Fund Performance and Metrics - The Hang Seng Healthcare ETF has seen a net asset growth of 715 million yuan over the past year, ranking in the top third among comparable funds [4]. - As of April 24, 2025, the ETF's net value increased by 41.16% over the past year, with a maximum monthly return of 28.34% since inception [4]. - The ETF's Sharpe ratio was reported at 1.34, indicating strong risk-adjusted returns [5]. Group 5: Valuation and Holdings - The latest price-to-earnings ratio (PE-TTM) for the HSHCI is 25.11, which is below 92.78% of the historical data over the past year, indicating a low valuation [5]. - The top ten weighted stocks in the HSHCI account for 57.54% of the index, with companies like BeiGene and WuXi Biologics being significant contributors [5].

Core Viewpoint - China National Pharmaceutical Group's PD-1 monoclonal antibody, Anike (Paimupili injection), has received FDA approval for treating recurrent or metastatic nasopharyngeal carcinoma (NPC) as a first-line therapy and for patients who have failed platinum-based chemotherapy [1][2] Company Summary - Anike is the first innovative drug product from China National Pharmaceutical Group to be approved in the U.S. market [1] - The drug has already been approved for four indications in China, including first-line and subsequent treatment for advanced NPC, and two additional indications for lung cancer and Hodgkin lymphoma [1] - The FDA previously granted breakthrough therapy designation, orphan drug status, and fast track designation for Anike in treating NPC [2] - The CEO of China National Pharmaceutical Group emphasized that the U.S. approval reflects the alignment of China's innovative drug development with international standards and aims to provide new immunotherapy options for NPC patients globally [2] Industry Summary - In 2018, there were approximately 129,000 new cases of NPC globally, accounting for 0.7% of all cancer diagnoses [3] - Over 70% of NPC patients are diagnosed at an advanced stage, and those with recurrent/metastatic NPC have a poor prognosis, with a median overall survival of less than 20 months [3] - There is a significant unmet clinical need for effective treatments for advanced NPC patients [3]

Core Insights - China National Pharmaceutical Group has 12 clinical studies selected for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) annual meeting, with 4 studies included in the "Latest Breakthrough Abstracts" [2][3] - The ASCO annual meeting is recognized as a leading global event in clinical oncology, showcasing over 40 innovative results from China National Pharmaceutical Group, covering more than 10 innovative drugs in various advanced fields such as ADC and bispecific antibodies [2] - Among the 12 oral presentations, 4 studies focus on "Bemarituzumab + Anlotinib Capsules," while 5 studies involve Anlotinib alone or in combination with other therapies [2] Group 1 - The phase III clinical study comparing "Bemarituzumab + Anlotinib" to Pembrolizumab for first-line treatment of PD-L1 positive advanced non-small cell lung cancer has been selected for the "Latest Breakthrough Abstract," with data to be presented on June 1 [2] - Two additional phase III studies on "Bemarituzumab + Anlotinib" for consolidation therapy after synchronous or sequential chemoradiotherapy and for first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer have also been selected for oral presentation [2] Group 2 - The HER2 bispecific antibody ADC drug TQB2102 will present its first human study data for advanced solid tumors at the ASCO meeting [3] - The ASCO meeting is scheduled to take place from May 30 to June 3 in Chicago, USA, with over 50 studies from 22 Chinese pharmaceutical companies selected for oral presentations [3] - Most abstract content will be published on the conference website on May 22, apart from the "Latest Breakthrough Abstracts" [3]

Group 1 - The annual American Society of Clinical Oncology (ASCO) meeting is set to showcase a record number of clinical studies from China National Pharmaceutical Group, with 12 oral presentations and 40 innovative results overall [1][2] - Among the highlighted studies, the combination of Bemarituzumab and Anlotinib is particularly notable, with four presentations focusing on its efficacy against PD-L1 positive advanced non-small cell lung cancer (NSCLC) [2][3] - The ASCO meeting will also feature significant data on Anlotinib, which has been involved in nine studies, marking a milestone for domestic innovative drugs [4] Group 2 - The HER2 bispecific antibody ADC, TQB2102, will present its first human study data at ASCO, with no similar products currently on the market [5] - The CCR8 monoclonal antibody, LM108, will also be discussed, highlighting its potential in pancreatic cancer treatment [5] - The ASCO meeting will take place from May 30 to June 3 in Chicago, with over 50 studies from 22 Chinese pharmaceutical companies included in the oral presentation segment [6]

Core Insights - The Chinese innovative drug market is projected to exceed 1.13 trillion yuan in 2024, with expectations to approach 2.3 trillion yuan by 2030, indicating a high growth trend in the sector [1] - The Hong Kong pharmaceutical ETF (159718) has shown a recent decline of 0.28%, but has increased by 7.16% over the past week [1] - The liquidity of the Hong Kong pharmaceutical ETF is active, with a turnover of 17.21% and a transaction volume of 50.91 million yuan [2] Group 1: Market Performance - As of April 24, 2025, notable stock performances include Xintai Medical (02291) up 13.86%, Ascentage Pharma-B (06855) up 7.36%, and Innovent Biologics (01801) up 4.18% [1] - The Medical Innovation ETF (516820) has a recent turnover of 1.7% and a transaction volume of 28.42 million yuan, with an average daily transaction of 53.10 million yuan over the past month [4] Group 2: Index and Weighting - The CSI Hong Kong Stock Connect Healthcare Index (930965) includes 50 liquid and large-cap healthcare companies, with the top ten stocks accounting for 59.76% of the index [6] - The top ten stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) account for 66.49%, indicating a concentration in leading companies [9] Group 3: Investment Outlook - The manager of Ping An Healthcare Fund, Zhou Sicong, emphasizes that the export of innovative drugs is largely unaffected by U.S. tariff policies due to factors such as high profit margins and the nature of intellectual property [2] - The innovative drug sector is expected to have a promising outlook for Chinese companies, with investors advised not to overreact to short-term policy fluctuations [2]